3 Results for "

AST2818

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "AST2818" in MCE Product Catalog:

6
6 Cited Publications
Referencia número: HY-112870
No. CAS: 1869057-83-9
Pureza:  99.89%
Synonyms: Alflutinib; Furmonertinib; AST2818
Target:  

EGFR

Áreas de investigación:  

Cancer

Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation .
loading...
    loading...
6
6 Cited Publications
Referencia número: HY-112870A
No. CAS: 2130958-55-1
Pureza:  99.97%
Synonyms: Alflutinib mesylate; Furmonertinib mesylate; AST2818 mesylate
Target:  

EGFR

Áreas de investigación:  

Inflammation/Immunology Cancer

Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation .
loading...
    loading...
Referencia número: HY-112870AS
Synonyms: Alflutinib-d3 mesylate; Furmonertinib-d3 mesylate; AST2818-d3 mesylate
Firmonertinib-d3 (Alflutinib-d3) mesylate is the deuterium labeled Firmonertinib mesylate (HY-112870A). Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.
loading...
    loading...